$200K - $250K*
Neurocrine Biosciences (Nasdaq: NBIX) is a neuroscience-focused, biopharmaceutical company with more than 25 years of experience discovering and developing life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. Headquartered in San Diego, Neurocrine Biosciences specializes in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems.
The company's diverse portfolio includes two FDA-approved treatments INGREZZA® (valbenazine) for tardive dyskinesia and ORILISSA® (elagolix) for endometriosis*, as well as clinical development programs in multiple therapeutic areas, including Parkinson's disease, chorea in Huntington disease, congenital adrenal hyperplasia, uterine fibroids* and polycystic ovary syndrome.* As part of a strategic collaboration with Voyager Therapeutics, Neurocrine Biosciences is also
Valid through: 2020-5-20
$80K - $100K
6 days ago